• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IV A期子宫颈原发性恶性黑色素瘤患者的根治性手术及辅助溶瘤病毒Rigvir治疗：一例报告

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir therapy: A case report.

作者信息

Pumpure Elizabete, Dručka Eva, Kigitoviča Dana, Meškauskas Raimundas, Isajevs Sergejs, Nemiro Ineta, Rasa Agnija, Olmane Evija, Zablocka Tatjana, Alberts Pēteris, Doniņa Simona

机构信息

Department of Obstetrics and Gynaecology Riga Stradiņš University Riga Latvia.

Riga Maternity Hospital Riga Latvia.

出版信息

Clin Case Rep. 2020 May 22;8(8):1538-1543. doi: 10.1002/ccr3.2928. eCollection 2020 Aug.

DOI:10.1002/ccr3.2928
PMID:32884791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7455402/
Abstract

Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression-free survival are good.

摘要

子宫颈原发性恶性黑色素瘤是一种罕见疾病，预后较差且复发率高。我们将Rigvir用作一名IVA期患者的辅助治疗。耐受性、总生存期和无进展生存期均良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/89af937011bf/CCR3-8-1538-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/ebdb5870e669/CCR3-8-1538-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/12e4a3c35a69/CCR3-8-1538-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/f8d5169d9be2/CCR3-8-1538-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/782629fed95f/CCR3-8-1538-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/89af937011bf/CCR3-8-1538-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/ebdb5870e669/CCR3-8-1538-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/12e4a3c35a69/CCR3-8-1538-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/f8d5169d9be2/CCR3-8-1538-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/782629fed95f/CCR3-8-1538-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a29f/7455402/89af937011bf/CCR3-8-1538-g005.jpg

相似文献

1
Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir therapy: A case report.IV A期子宫颈原发性恶性黑色素瘤患者的根治性手术及辅助溶瘤病毒Rigvir治疗：一例报告
Clin Case Rep. 2020 May 22;8(8):1538-1543. doi: 10.1002/ccr3.2928. eCollection 2020 Aug.
2
The advent of oncolytic virotherapy in oncology: The Rigvir® story.肿瘤溶瘤病毒治疗在肿瘤学中的应用：Rigvir®的故事。
Eur J Pharmacol. 2018 Oct 15;837:117-126. doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1.
3
ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report.溶瘤病毒ECHO-7 Rigvir®用于I期葡萄膜黑色素瘤辅助治疗的回顾性病例报告
Am J Ophthalmol Case Rep. 2020 Jan 31;17:100615. doi: 10.1016/j.ajoc.2020.100615. eCollection 2020 Mar.
4
Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.一项回顾性研究表明，经改良的ECHO-7病毒Rigvir免疫疗法（溶瘤病毒疗法）可延长黑色素瘤患者肿瘤手术切除后的生存期。
Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180.
5
Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.ECHO-7 溶瘤病毒 Rigvir 治疗 IIA 期皮肤黑色素瘤。
Perm J. 2022 Sep 14;26(3):139-144. doi: 10.7812/TPP/21.232. Epub 2022 Aug 11.
6
Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.一名IV期M1c黑色素瘤患者、一名IIIA期小细胞肺癌患者和一名IV期组织细胞肉瘤患者接受溶瘤ECHO-7病毒Rigvir的长期治疗——三例病例报告
APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26.
7
Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin .溶瘤性ECHO-7病毒Rigvir®对人源细胞系活力的影响
J Cancer. 2018 Feb 28;9(6):1033-1049. doi: 10.7150/jca.23242. eCollection 2018.
8
A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report.1例采用溶瘤性ECHO-7病毒治疗的进展期IIIB期黑色素瘤：病例报告
SAGE Open Med Case Rep. 2020 Jun 23;8:2050313X20934978. doi: 10.1177/2050313X20934978. eCollection 2020.
9
Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report.使用ECHO-7溶瘤病毒Rigvir治疗未知原发灶的黑色素瘤脑转移：一例报告
Front Oncol. 2018 Feb 26;8:43. doi: 10.3389/fonc.2018.00043. eCollection 2018.
10
Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir.肾上腺及胃恶性黑色素瘤，无皮肤病变证据，采用溶瘤病毒Rigvir治疗
Case Rep Oncol. 2020 Apr 17;13(1):424-430. doi: 10.1159/000506978. eCollection 2020 Jan-Apr.

引用本文的文献

1
Primary Melanoma of the Cervix Uteri: A Systematic Review and Meta-Analysis of the Reported Cases.子宫颈原发性黑色素瘤：对报告病例的系统评价和荟萃分析
Biology (Basel). 2023 Mar 2;12(3):398. doi: 10.3390/biology12030398.
2
Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials.溶瘤病毒在癌症免疫治疗中的治疗应用：挑战与当前临床试验综述
J Biomed Sci Res. 2022;4(2). doi: 10.36266/JBSR/164. Epub 2022 Oct 20.
3
Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series.

本文引用的文献

1
Cancer of the cervix uteri.子宫颈癌。
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36. doi: 10.1002/ijgo.12611.
2
The advent of oncolytic virotherapy in oncology: The Rigvir® story.肿瘤溶瘤病毒治疗在肿瘤学中的应用：Rigvir®的故事。
Eur J Pharmacol. 2018 Oct 15;837:117-126. doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1.
3
Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin .溶瘤性ECHO-7病毒Rigvir®对人源细胞系活力的影响
宫颈原发性恶性黑色素瘤：病例报告与系列病例的综合分析
Front Oncol. 2022 Jun 22;12:913964. doi: 10.3389/fonc.2022.913964. eCollection 2022.
4
Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.利用溶瘤病毒进行癌症治疗的组合方法：通过临床试验结果预测前景。
Viruses. 2021 Jun 29;13(7):1271. doi: 10.3390/v13071271.
J Cancer. 2018 Feb 28;9(6):1033-1049. doi: 10.7150/jca.23242. eCollection 2018.
4
Primary malignant melanoma of cervix and vagina.宫颈和阴道原发性恶性黑色素瘤。
Obstet Gynecol Sci. 2016 Sep;59(5):415-20. doi: 10.5468/ogs.2016.59.5.415. Epub 2016 Sep 13.
5
Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.一项回顾性研究表明，经改良的ECHO-7病毒Rigvir免疫疗法（溶瘤病毒疗法）可延长黑色素瘤患者肿瘤手术切除后的生存期。
Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180.
6
Immunotherapy of melanoma: present options and future promises.黑色素瘤的免疫疗法：当前选择与未来前景
Cancer Metastasis Rev. 2015 Mar;34(1):115-28. doi: 10.1007/s10555-014-9542-0.
7
Primary malignant melanoma of uterine cervix: a suggestion of new scheme of treatment combination.宫颈原发性恶性黑色素瘤：一种新的治疗联合方案建议。
Chin J Cancer Res. 2014 Jun;26(3):351-4. doi: 10.3978/j.issn.1000-9604.2014.06.03.
8
Management of vulvar and vaginal melanomas: current and future strategies.外阴和阴道黑色素瘤的管理：当前及未来策略
Am Soc Clin Oncol Educ Book. 2014:e277-81. doi: 10.14694/EdBook_AM.2014.34.e277.
9
Primary malignant melanoma of uterine cervix FIGO IIa1: A case report with 40 months ongoing survival and literature review.子宫颈原发性恶性黑色素瘤FIGO IIa1期：1例生存40个月的病例报告及文献复习
Gynecol Oncol Case Rep. 2013 Apr 23;5:52-4. doi: 10.1016/j.gynor.2013.04.004. eCollection 2013.
10
Primary malignant melanoma of the vagina: a retrospective clinicopathologic study of 44 cases.阴道原发性恶性黑色素瘤：44 例回顾性临床病理研究。
Int J Gynecol Cancer. 2014 Jan;24(1):149-55. doi: 10.1097/IGC.0000000000000013.